Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Variation in therapeutic strategies for the management of severe COVID-19 in India- A nationwide cross-sectional survey
Jagiasi et al., The International Journal of Clinical Practice, doi:10.1111/ijcp.14574 (Review)
Jagiasi et al., Variation in therapeutic strategies for the management of severe COVID-19 in India- A nationwide.., The International Journal of Clinical Practice, doi:10.1111/ijcp.14574 (Review)
Jun 2021   Source   PDF  
  All Studies   Meta
Survey of medication use for severe COVID-19 in India, showing 33% adoption of ivermectin as of January 2021.
Jagiasi et al., 25 Jun 2021, peer-reviewed, 19 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Received: 1 March 2021 | Revised: 22 June 2021 | Accepted: 24 June 2021 DOI: 10.1111/ijcp.14574 ORIG INAL PAPER Respiratory Medicine Variation in therapeutic strategies for the management of severe COVID-­19 in India: A nationwide cross-­sectional survey Bharat Jagiasi1 | Prashant Nasa2 | Gunjan Chanchalani3 | Ahsan Ahmed4 | Ajith Kumar AK5 | Kanwalpreet Sodhi6 | Kishore Mangal7 | Manoj K. Singh8 | Nitesh Gupta9 | Prasanna U. Bidkar10 | Ranvir S. Tyagi11 | Reshu G. Khanikar12 | Swagata Tripathy13 | Swapna Khanzode14 | Kesavarapu Subba Reddy15 | Saurabh Saigal16 | Vijay Anand Sivakumar17 | Yash Javeri18 | Seema S. Tekwani19 1 Critical Care Department, Reliance Hospital, Navi Mumbai, Maharashtra, India 2 Critical Care Medicine, NMC Specialty Hospital, Dubai, United Arab Emirates 3 Critical Care Medicine, Cumballa Hill Hospital, Mumbai, Maharashtra, India 4 Anesthesiology and Critical Care, KPC Medical College and Hospital, Kolkata, West Bengal, India 5 Critical Care Medicine, Manipal Hospitals, Bengaluru, Karnataka, India 6 Department of Critical Care, Deep Hospital, Ludhiana, Punjab, India 7 Critical Care, Eternal Hospital, Jaipur, Rajasthan, India 8 Critical Care & Sleep Medicine, Apollo Hospital, Ahmedabad, Gujarat, India 9 Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, New Delhi, India 10 Department of Anaesthesiology and Critical Care, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India 11 Department of Anaesthesia and Critical Care Medicine, Synergy Plus Hospital, Agra, Uttar Pradesh, India 12 Department of Critical Care Medicine, Health City Hospital, Guwahati, Assam, India 13 Anesthesia & Intensive Care, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India 14 Medicine and Critical Care, Wockhardt Multispecialty Hospital, Nagpur, Maharashtra, India 15 Department Of Critical Care Medicine, Apollo Health City, Hyderabad, Telangana, India 16 Anaesthesia and Intensive Care, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India 17 Velammal Medical college and Research Centre, Madurai, Tamil Nadu, India 18 Critical Care Medicine and Emergency Medicine, Regency Super Specialty Hospital, Lucknow, Uttar Pradesh, India 19 Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA, USA Correspondence Prashant Nasa, Critical Care Medicine, NMC Specialty Hospital, PO box 7832, Al Nahda-­2, Dubai, United Arab Emirates. Email: Abstract Aim: During the pandemic of coronavirus disease 2019 (COVID-­19), the physicians are using various off-­label therapeutics to manage COVID-­19. We undertook a cross-­ sectional survey to study the current variation in therapeutic strategies for managing severe COVID-­19 in India. Methods: From January 4 to January 18, 2021, an online cross-­sectional survey was conducted among physicians involved in the management of severe COVID-­19. The survey had three sections: 1. Antiviral agents, 2. Immunomodulators, and 3. Adjuvant therapies. Results: 1055 respondents (from 24 states and five union territories), of which 64.2% were consultants, 54.3% working in private hospitals, and 39.1% were from critical care medicine completed the survey. Remdesivir (95.2%), antithrombotics (94.2%), Int J Clin Pract...
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop